Bristol-Myers Squibb: Business Development in a Global Community

In this exclusive interview, Fintan Walton talks to Graham Brazier, Vice President and Head of Business Development at Bristol-Myers Squibb (BMS), about the world of big pharma business development and the process of in-licensing. Because the interview took place at the AusBiotech 2007 conference, particular reference is made to the importance and challenges of making deals in Australia. Graham also details the rationale between BMS’ collaborations with fellow big pharma companies AstraZeneca and Pfizer, as well as discussing BMS’ acquisition of Adnexus.

 

About Graham Brazier

Before joining Bristol-Myers Squibb as Vice President and Head of Business Development in April 2002, Graham Brazier was Senior Vice President, Corporate Development, 3-Dimensional Pharmaceuticals, where he was responsible for business and corporate development as well as developing and maintaining relationships with investment banks and the investment community. Before this, he was Vice President, Worldwide Business Development, Pharmaceuticals, at SmithKline Beecham (now GlaxoSmithKline), responsible for co-promotion agreements, in- and out-licensing, research collaborations, patent licences, biotech acquisitions and various other strategic alliances.

 

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global pharmaceutical and related healthcare products company. Its aim is to discover and develop innovative, cost-effective medicines that address significant unmet medical need and enhance and extend human life. The company is working to discover and develop treatments specifically for cancer, atherosclerosis/thrombosis, diabetes and obesity.